Do analysts rate GRML or ASBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenland Mines Ltd. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GRML or ASBP more profitable?

Aspire Biopharma's return on equity of 0.00% beat Greenland Mines Ltd. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Greenland Mines Ltd. Common Stock N/A -109.40% -98.80% Aspire Biopharma N/A N/A -398.04%

Do analysts prefer BGM or ASBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, BGM or ASBP?

BGM Group has higher revenue and earnings than Aspire Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $25.10M 1.20 -$1.44M N/A N/A Aspire Biopharma $10K 795.47 -$24.48M -$116.67 N/A

Is BGM or ASBP more profitable?

Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A Aspire Biopharma N/A N/A -398.04%

Do analysts rate ASBP or DARE?

Dare Bioscience has a consensus target price of $10.00, indicating a potential upside of 384.26%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is ASBP or DARE more profitable?

Company Net Margins Return on Equity Return on Assets Aspire Biopharma N/A N/A -398.04% Dare Bioscience N/A N/A -46.22%

Do analysts rate KALA or ASBP?

KALA BIO currently has a consensus target price of $1,158.33, indicating a potential upside of 113,462.09%. Given KALA BIO's stronger consensus rating and higher probable upside, equities analysts clearly believe KALA BIO is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is KALA or ASBP more profitable?

Aspire Biopharma's return on equity of 0.00% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -1,336.10% -94.85% Aspire Biopharma N/A N/A -398.04%

Do analysts rate ASBP or KYNB?

Kyntra Bio has a consensus price target of $32.50, suggesting a potential upside of 342.48%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has stronger valuation & earnings, ASBP or KYNB?

Kyntra Bio has higher revenue and earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aspire Biopharma $10K 795.47 -$24.48M -$116.67 N/A Kyntra Bio $6.44M 4.62 $183.45M $40.46 0.18

Is ASBP or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Aspire Biopharma's net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Aspire Biopharma N/A N/A -398.04% Kyntra Bio 2,199.13% N/A -36.71%

Aspire Biopharma (ASBP) Competitors

$6.12 +0.09 (+1.48%)

Closing price 03:58 PM Eastern

Extended Trading

$6.08 -0.04 (-0.62%)

As of 04:01 PM Eastern

Compare

ASBP vs. GRML, BGM, DARE, KALA, and KYNB

Should you buy Aspire Biopharma stock or one of its competitors? MarketBeat compares Aspire Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aspire Biopharma include Greenland Mines Ltd. Common Stock (GRML), BGM Group (BGM), Dare Bioscience (DARE), KALA BIO (KALA), and Kyntra Bio (KYNB). These companies are all part of the "pharmaceutical products" industry.

How does Aspire Biopharma compare to Greenland Mines Ltd. Common Stock?

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

20.1% of Greenland Mines Ltd. Common Stock shares are owned by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are owned by institutional investors. 11.3% of Greenland Mines Ltd. Common Stock shares are owned by company insiders. Comparatively, 5.8% of Aspire Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aspire Biopharma's return on equity of 0.00% beat Greenland Mines Ltd. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenland Mines Ltd. Common Stock	N/A	-109.40%	-98.80%
Aspire Biopharma	N/A	N/A	-398.04%

Greenland Mines Ltd. Common Stock has higher earnings, but lower revenue than Aspire Biopharma. Greenland Mines Ltd. Common Stock is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenland Mines Ltd. Common Stock	N/A	N/A	-$10.55M	-$0.32	N/A
Aspire Biopharma	$10K	795.47	-$24.48M	-$116.67	N/A

In the previous week, Greenland Mines Ltd. Common Stock had 4 more articles in the media than Aspire Biopharma. MarketBeat recorded 6 mentions for Greenland Mines Ltd. Common Stock and 2 mentions for Aspire Biopharma. Aspire Biopharma's average media sentiment score of 1.43 beat Greenland Mines Ltd. Common Stock's score of 0.45 indicating that Aspire Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Greenland Mines Ltd. Common Stock	Neutral
Aspire Biopharma	Positive

Greenland Mines Ltd. Common Stock has a beta of 7.05, meaning that its stock price is 605% more volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenland Mines Ltd. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Greenland Mines Ltd. Common Stock beats Aspire Biopharma on 7 of the 11 factors compared between the two stocks.

How does Aspire Biopharma compare to BGM Group?

BGM Group (NASDAQ:BGM) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

BGM Group has higher revenue and earnings than Aspire Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$25.10M	1.20	-$1.44M	N/A	N/A
Aspire Biopharma	$10K	795.47	-$24.48M	-$116.67	N/A

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Aspire Biopharma	N/A	N/A	-398.04%

19.2% of Aspire Biopharma shares are owned by institutional investors. 58.7% of BGM Group shares are owned by insiders. Comparatively, 5.8% of Aspire Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BGM Group has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market.

In the previous week, BGM Group had 3 more articles in the media than Aspire Biopharma. MarketBeat recorded 5 mentions for BGM Group and 2 mentions for Aspire Biopharma. Aspire Biopharma's average media sentiment score of 1.43 beat BGM Group's score of 0.69 indicating that Aspire Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
BGM Group	Positive
Aspire Biopharma	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

BGM Group beats Aspire Biopharma on 6 of the 9 factors compared between the two stocks.

How does Aspire Biopharma compare to Dare Bioscience?

Aspire Biopharma (NASDAQ:ASBP) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

In the previous week, Aspire Biopharma and Aspire Biopharma both had 2 articles in the media. Aspire Biopharma's average media sentiment score of 1.43 beat Dare Bioscience's score of 0.94 indicating that Aspire Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Aspire Biopharma	Positive
Dare Bioscience	Positive

Aspire Biopharma has a beta of 0.15, suggesting that its share price is 85% less volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Dare Bioscience has higher revenue and earnings than Aspire Biopharma. Dare Bioscience is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	795.47	-$24.48M	-$116.67	N/A
Dare Bioscience	$1.16M	26.73	-$13.40M	-$0.95	N/A

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by insiders. Comparatively, 4.1% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dare Bioscience has a consensus target price of $10.00, indicating a potential upside of 384.26%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-398.04%
Dare Bioscience	N/A	N/A	-46.22%

Summary

Dare Bioscience beats Aspire Biopharma on 8 of the 13 factors compared between the two stocks.

How does Aspire Biopharma compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

Aspire Biopharma has higher revenue and earnings than KALA BIO. Aspire Biopharma is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
Aspire Biopharma	$10K	795.47	-$24.48M	-$116.67	N/A

Aspire Biopharma's return on equity of 0.00% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-1,336.10%	-94.85%
Aspire Biopharma	N/A	N/A	-398.04%

KALA BIO has a beta of -2.35, indicating that its stock price is 335% less volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.15, indicating that its stock price is 85% less volatile than the broader market.

In the previous week, KALA BIO had 1 more articles in the media than Aspire Biopharma. MarketBeat recorded 3 mentions for KALA BIO and 2 mentions for Aspire Biopharma. Aspire Biopharma's average media sentiment score of 1.43 beat KALA BIO's score of 0.47 indicating that Aspire Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
KALA BIO	Neutral
Aspire Biopharma	Positive

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by insiders. Comparatively, 5.8% of Aspire Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

KALA BIO currently has a consensus target price of $1,158.33, indicating a potential upside of 113,462.09%. Given KALA BIO's stronger consensus rating and higher probable upside, equities analysts clearly believe KALA BIO is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

KALA BIO beats Aspire Biopharma on 8 of the 14 factors compared between the two stocks.

How does Aspire Biopharma compare to Kyntra Bio?

Aspire Biopharma (NASDAQ:ASBP) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by company insiders. Comparatively, 4.2% of Kyntra Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aspire Biopharma has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market. Comparatively, Kyntra Bio has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Kyntra Bio has a consensus price target of $32.50, suggesting a potential upside of 342.48%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Kyntra Bio has a net margin of 2,199.13% compared to Aspire Biopharma's net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-398.04%
Kyntra Bio	2,199.13%	N/A	-36.71%

In the previous week, Aspire Biopharma and Aspire Biopharma both had 2 articles in the media. Aspire Biopharma's average media sentiment score of 1.43 beat Kyntra Bio's score of 0.93 indicating that Aspire Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Aspire Biopharma	Positive
Kyntra Bio	Positive

Kyntra Bio has higher revenue and earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	795.47	-$24.48M	-$116.67	N/A
Kyntra Bio	$6.44M	4.62	$183.45M	$40.46	0.18

Summary

Kyntra Bio beats Aspire Biopharma on 12 of the 15 factors compared between the two stocks.

Get Aspire Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASBP vs. The Competition

Export

Metric	Aspire Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.96M	$3.67B	$6.76B	$12.66B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-0.05	21.47	27.10	24.38
Price / Sales	795.47	329.21	525.30	91.65
Price / Cash	N/A	143.66	48.59	59.39
Price / Book	-0.11	8.58	10.82	6.32
Net Income	-$24.48M	$23.88M	$3.59B	$331.55M
7 Day Performance	5.87%	-2.33%	-1.24%	0.08%
1 Month Performance	8.30%	6.48%	3.11%	-0.74%
1 Year Performance	-98.40%	53.33%	29.11%	20.69%

Aspire Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASBP Aspire Biopharma	0.5113 of 5 stars	$6.12 +1.5%	N/A	-98.5%	$7.96M	$10K	N/A	N/A	Positive News Short Interest Decrease
GRML Greenland Mines Ltd. Common Stock	0.2478 of 5 stars	$0.23 flat	N/A	-85.6%	$32.05M	N/A	N/A	5	Gap Up
BGM BGM Group	0.9523 of 5 stars	$0.32 flat	N/A	-96.1%	$31.50M	$25.10M	N/A	298	News Coverage Short Interest Decrease
DARE Dare Bioscience	2.455 of 5 stars	$2.09 flat	$10.00 +378.5%	-33.0%	$31.31M	$1.16M	N/A	30
KALA KALA BIO	2.0552 of 5 stars	$1.68 flat	$1,018.75 +60,539.9%	-99.7%	$31.23M	N/A	N/A	30	News Coverage Analyst Downgrade Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASBP) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aspire Biopharma (ASBP) Competitors

ASBP vs. GRML, BGM, DARE, KALA, and KYNB

How does Aspire Biopharma compare to Greenland Mines Ltd. Common Stock?

Summary

How does Aspire Biopharma compare to BGM Group?

Summary

How does Aspire Biopharma compare to Dare Bioscience?

Summary

How does Aspire Biopharma compare to KALA BIO?

Summary

How does Aspire Biopharma compare to Kyntra Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASBP vs. The Competition

Aspire Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aspire Biopharma (ASBP) Competitors

ASBP vs. GRML, BGM, DARE, KALA, and KYNB

How does Aspire Biopharma compare to Greenland Mines Ltd. Common Stock?

Do institutionals and insiders hold more shares of GRML or ASBP?

Is GRML or ASBP more profitable?

Which has better earnings & valuation, GRML or ASBP?

Does the media prefer GRML or ASBP?

Which has more risk & volatility, GRML or ASBP?

Do analysts rate GRML or ASBP?

Summary

How does Aspire Biopharma compare to BGM Group?

Which has stronger earnings & valuation, BGM or ASBP?

Is BGM or ASBP more profitable?

Do insiders & institutionals believe in BGM or ASBP?

Which has more volatility & risk, BGM or ASBP?

Does the media refer more to BGM or ASBP?

Do analysts prefer BGM or ASBP?

Summary

How does Aspire Biopharma compare to Dare Bioscience?

Does the media prefer ASBP or DARE?

Which has more risk and volatility, ASBP or DARE?

Which has preferable valuation & earnings, ASBP or DARE?

Do insiders and institutionals have more ownership in ASBP or DARE?

Do analysts rate ASBP or DARE?

Is ASBP or DARE more profitable?

Summary

How does Aspire Biopharma compare to KALA BIO?

Which has stronger earnings & valuation, KALA or ASBP?

Is KALA or ASBP more profitable?

Which has more volatility and risk, KALA or ASBP?

Does the media prefer KALA or ASBP?

Do institutionals & insiders believe in KALA or ASBP?

Do analysts rate KALA or ASBP?

Summary

How does Aspire Biopharma compare to Kyntra Bio?

Do institutionals and insiders hold more shares of ASBP or KYNB?

Which has more risk & volatility, ASBP or KYNB?

Do analysts rate ASBP or KYNB?

Is ASBP or KYNB more profitable?

Does the media favor ASBP or KYNB?

Which has stronger valuation & earnings, ASBP or KYNB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASBP vs. The Competition

Aspire Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools